4 active not recruiting, 4 recruiting, 1 completed, 1 not yet recruiting. 6 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Active not recruiting 2, Completed 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow this condition Literature Review of Metastatic Esophageal Adenocarcinoma trials Research Report on Metastatic Esophageal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma Ivonescimab, FOLFOX regimen, Irinotecan - Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 88 | 2025-11-20 | 2026-04-28 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 224 | 2024-06-24 | 2026-10-21 |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer AgenT-797, Botensilimab, Balstilimab - Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-02-01 | 2026-05-15 |
| Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 40 | 2023-03-07 | 2025-12-16 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Fluorouracil, Leucovorin Calcium, Oxaliplatin - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 382 | 2023-01-31 | 2026-10-02 |
| Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca Abemaciclib, Ramucirumab - Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Completed | Baylor Research Institute | 26 | 2021-06-11 | 2026-09-14 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Adavosertib, Radiation Therapy - Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2021-04-09 | 2026-07-31 |
| Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Capecitabine, Fluorouracil, Leucovorin - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 314 | 2020-05-26 | 2026-10-19 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel - Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2010-09-21 | 2026-09-10 |
Adenocarcinoma Of Esophagus (10) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Meningeal Carcinomatosis (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Stomach Neoplasms (1)
Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Esophageal Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Carcinoma, Squamous Cell (2) · Neoplasms, Squamous Cell (2) · Brain Diseases (1) · Central Nervous System Diseases (1)
Paclitaxel (5) · Fluorouracil (4) · Leucovorin (4) · Oxaliplatin (4) · Ramucirumab (4) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Taxes (3) · dehydroftorafur (3) · Irinotecan (2) · Nivolumab (2) · Radiation (2) · Radiotherapy (2) · Biopsy (1) · Capecitabine (1)
National Cancer Institute (NCI) (3) · Alliance for Clinical Trials in Oncology (1) · Baylor Research Institute (1) · ECOG-ACRIN Cancer Research Group (1) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1) · Roswell Park Cancer Institute (1) · UNICANCER (1)
United States (9) · France (1) · Puerto Rico (1)
Anwaar Saeed (1) · Eric D Miller (1) · Gladys Rodriguez, MD (1) · Kannan Thanikachalam (1) · Nataliya V Uboha (1) · Ronan Kelly, MD (1) · Steven J Cohen (1) · Yelena Janjigian, MD (1)
PMID 35602670, PMID 37104870, PMID 40155326, PMID 42669571
U10CA180820 (2), 2025 (1), P30CA060553 (1), U10CA021115 (1), U10CA180888 (1), UM1CA186712 (1)